This is not a healthy balance sheet, but it is a controversial valuation setup. A Forward P/E of 9.2 suggests the market expects stabilization and normalized earnings despite a catastrophic trailing EPS of -1,719.30 and a deeply negative -24.30% operating margin. The Altman Z-Score of 0.8 signals genuine financial distress risk, and a -15.80% ROE confirms shareholder value destruction. The market is not mispricing strength here—it is pricing survival and potential restructuring; this is a leveraged turnaround speculation, not a quality compounder.